Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II
暂无分享,去创建一个
H. Genant | D. M. van der Heijde | T. Yoneda | H. Yamanaka | Yoshiya Tanaka | T. Takeuchi | N. Ishiguro | N. Okubo | Takeshi Ohira
[1] F. Lafeber,et al. Associations of CTX-II with biochemical markers of bone turnover raise questions about its tissue origin: new insights from CHECK , 2014, Annals of the rheumatic diseases.
[2] F. Lafeber,et al. Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis , 2012, Annals of the rheumatic diseases.
[3] Toshitaka Nakamura,et al. Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis , 2012, Osteoporosis International.
[4] S. Saevarsdottir,et al. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial , 2011, Annals of the rheumatic diseases.
[5] Maurizio Cutolo,et al. Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.
[6] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[7] P. Kostenuik,et al. Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] D. M. van der Heijde,et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. , 2008, Arthritis and rheumatism.
[9] Y. Yazici,et al. Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.
[10] J. Zwerina,et al. Mechanisms of Disease: the link between RANKL and arthritic bone disease , 2005, Nature Clinical Practice Rheumatology.
[11] A. Chott,et al. Interaction between Synovial Inflammatory Tissue and Bone Marrow in Rheumatoid Arthritis 1 , 2005, The Journal of Immunology.
[12] B. Bolon,et al. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. , 2002, Arthritis and rheumatism.
[13] D L Lacey,et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. , 2000, The American journal of pathology.
[14] A. Zwinderman,et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. , 1999, Arthritis and rheumatism.
[15] P. Shekelle,et al. How to read radiographs according to the Sharp/van der Heijde method. , 1999 .
[16] Yongwon Choi,et al. TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts , 1998, The Journal of experimental medicine.
[17] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[18] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[19] B. Bresnihan,et al. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. , 1996, British journal of rheumatology.
[20] J J Anderson,et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[21] R. Chang,et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. , 1992, Arthritis and rheumatism.
[22] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[23] Williams Da,et al. A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control , 1986 .
[24] E Shirley,et al. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. , 1977, Biometrics.
[25] G. Schett,et al. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. , 2007, Arthritis and rheumatism.
[26] Maarten Boers,et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. , 2004, Arthritis and rheumatism.
[27] D. A. Williams. A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. , 1986, Biometrics.
[28] C. Werning. [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.
[29] H. Holman,et al. Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.